Coherus Oncology
CHRS
169 hedge funds and large institutions have $348M invested in Coherus Oncology in 2023 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 63 increasing their positions, 48 reducing their positions, and 33 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
35% more call options, than puts
Call options by funds: $2.35M | Put options by funds: $1.74M
31% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 48
27% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 33
5% more funds holding
Funds holding: 161 → 169 (+8)
6% less capital invested
Capital invested by funds: $371M → $348M (-$23.4M)
7.13% less ownership
Funds ownership: 91.91% → 84.78% (-7.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$28.8M |
| 2 |
Barclays
London,
United Kingdom
|
+$10.6M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$6.02M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.31M |
| 5 |
Rafferty Asset Management
New York
|
+$4.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$19.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$15.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.4M |
| 4 |
Millennium Management
New York
|
-$2.94M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
-$2M |
CHRS Hedge Fund Activity: Q3 2023 in Review
169 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q3 2023, worth a combined $348M — down 6.3% from $371M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new CHRS positions and 33 closed out — a net gain of 9 holders — while 63 added to existing stakes and 48 trimmed.
The largest buyer was State Street, adding an estimated $28.8M. The largest seller was BlackRock, cutting an estimated $19.1M.
- 169 institutional investors held Coherus Oncology (CHRS) as of Q3 2023, up from 161 in Q2 2023.
- Funds reported $348M of Coherus Oncology stock for Q3 2023, down 6.3% quarter-over-quarter.
- 42 funds opened new Coherus Oncology positions in Q3 2023 and 33 closed out, a net change of +9 holders.
- The largest Coherus Oncology buyer in Q3 2023 was State Street, an estimated $28.8M added.
- The largest Coherus Oncology seller in Q3 2023 was BlackRock, an estimated $19.1M sold.
Based on aggregated 13F filings for Q3 2023.